Plus more pharma news from the Pharmalittle newsletter.

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

It looks likely we'll see oral GLP-1 drugs on the market by next year, with pharmaceutical company Eli Lilly reporting ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Weight-loss drugs like Ozempic too costly for Arizona patients on Medicaid, until obesity leads to diabetes Adnan Alam Jul 25, 2025 Updated Aug 1, 2025 Cronkite News Adnan Alam ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

Weight-loss drugs have boomed in recent years, but their cost has put pressure on employers.

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in treatment as well.